Antiallodynic effect of the high concentration lidocaine ointment in cancer pain, cross-over test

Antiallodynic effect of the high concentration lidocaine ointment in cancer pain, cross-over test - Antiallodynic effect of the high concentration lidocaine ointment

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021275

Enrollment

Registered

2016-04-01

Start date

2016-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer

Interventions

Interventions Group: the high concentration lidocaine ointment 2,4,8,24 hours after the application Control Group: placebo ointment 2,4,8,24 hours after the application

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Age>=20 Patient with cancer-related neuropathic pain Patient with allodynia NRS of static allodynia>=4 Expected at least one month survival

Exclusion criteria

Exclusion criteria: Patient with neuropathic pain by cancer treatment(chemotherapy-induced peripheral neuropathy etc.) Patient with cancer-unrelated neuropathic pain(postherpetic neuralgia etc.) Patients who changed analgesic and analgescic adjuvant agents within 2 days Uncontrolled psychiatric disease

Design outcomes

Primary

Measure	Time frame
Numerical Rating Scale in the static allodynia on 2 hours of the application	—

Countries

Japan

Contacts

Public ContactHideaki Hasuo

Kansai Medical University Department of Psychosomatic Medicine

h.hasuo7@gmail.com072-804-0101

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026